Kushwaha Avadhesh, Murthy Reena N, Murthy S Narasimha, Elkeeb Rania, Hui X, Maibach Howard I
a Institute for Drug Delivery and Biomedical Research , Bangalore , India .
b Department of Pharmaceutics , University of Mississippi, University , MS , USA , and.
Drug Dev Ind Pharm. 2015;41(10):1575-81. doi: 10.3109/03639045.2015.1033426. Epub 2015 May 22.
Onychomycosis, a common fungal infection in the finger and toe nails, affects approximately 2-8% of the worldwide population. Fungal infection is more complicated in those who suffer from conditions, such as diabetes, peripheral vascular diseases and compromised immune diseases.
Onychomycosis treatment has been classified on the basis of location of infection in the toes and fingers and infectious agents (dermatophytes fungi, yeast and non-dermatophyte molds). In this review, the available therapies (traditional and device based) and their limitations for the treatment of onychomycosis have been discussed.
The success rate with topical nail products has been minimal. The main reason for this poor success rate could be attributed to the lack of complete understanding of the pathophysiology of the disease and clinical pharmacokinetic data of drugs in the infected nail apparatus.
甲癣是手指和脚趾指甲常见的真菌感染,全球约2 - 8%的人口受其影响。对于患有糖尿病、外周血管疾病和免疫功能受损疾病等病症的人来说,真菌感染更为复杂。
甲癣治疗已根据感染在脚趾和手指的部位以及感染病原体(皮肤癣菌、酵母菌和非皮肤癣菌霉菌)进行分类。在本综述中,讨论了现有的治疗方法(传统方法和基于器械的方法)及其在治疗甲癣方面的局限性。
局部指甲产品的成功率极低。成功率低的主要原因可能是对该疾病的病理生理学以及感染指甲结构中药物的临床药代动力学数据缺乏全面了解。